Imagion Biosystems Raises AU$3.5 million to Advance Cancer Imaging Trials.

Imagion Biosystems Limited (ASX: IBX) has successfully secured AU$3.5 million through a well-supported capital raising led by CPS Capital. The funds will accelerate the company’s MagSense imaging technology, with a particular focus on the upcoming Phase 2 clinical trial for HER2+ Breast Cancer in the USA. The capital will also support early-stage programs targeting prostate and ovarian cancers, and the development of AI-powered molecular MRI platforms.

The placement consists of two tranches, offering new shares at AU$0.015 each with free-attaching listed options. Tranche 1 raised approximately AU$675,000 under existing capacity, while Tranche 2—raising the remaining AU$2.8 million—is subject to shareholder approval at the EGM scheduled for 18 September 2025. Company directors also committed AU$150,000, showing strong internal confidence. The proceeds will fund regulatory filings, clinical manufacturing, IP protection, and collaboration with MRI experts to enhance precision imaging and cancer diagnostics.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com